2,900 Shares in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Bought by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 2,900 shares of the biopharmaceutical company’s stock, valued at approximately $682,000.

Several other large investors have also recently bought and sold shares of the business. Vanguard Group Inc. raised its position in Alnylam Pharmaceuticals by 0.8% during the fourth quarter. Vanguard Group Inc. now owns 12,733,399 shares of the biopharmaceutical company’s stock worth $2,996,296,000 after acquiring an additional 98,303 shares during the last quarter. Regeneron Pharmaceuticals Inc. acquired a new position in Alnylam Pharmaceuticals during the 4th quarter worth approximately $1,045,822,000. Norges Bank purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $577,941,000. Geode Capital Management LLC grew its stake in shares of Alnylam Pharmaceuticals by 2.8% during the fourth quarter. Geode Capital Management LLC now owns 2,206,800 shares of the biopharmaceutical company’s stock valued at $518,367,000 after acquiring an additional 59,597 shares in the last quarter. Finally, American Century Companies Inc. raised its position in shares of Alnylam Pharmaceuticals by 0.7% in the 4th quarter. American Century Companies Inc. now owns 1,604,024 shares of the biopharmaceutical company’s stock valued at $377,443,000 after purchasing an additional 11,291 shares in the last quarter. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on ALNY shares. Needham & Company LLC reaffirmed a “buy” rating and issued a $320.00 price objective on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Bank of America increased their target price on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a “buy” rating in a report on Friday, March 21st. Wells Fargo & Company boosted their price objective on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a research report on Friday, March 21st. Citigroup raised their price objective on shares of Alnylam Pharmaceuticals from $338.00 to $351.00 and gave the company a “buy” rating in a research report on Friday, March 21st. Finally, Royal Bank of Canada raised their price objective on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an “outperform” rating in a research note on Friday, March 21st. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have given a buy rating to the stock. Based on data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $316.25.

Insider Activity at Alnylam Pharmaceuticals

In other news, Director Phillip A. Sharp sold 11,250 shares of the stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total transaction of $3,093,750.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 1,213 shares of Alnylam Pharmaceuticals stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the sale, the chief executive officer now owns 81,526 shares of the company’s stock, valued at approximately $20,802,989.42. The trade was a 1.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,234 shares of company stock worth $19,958,097 in the last 90 days. 1.50% of the stock is owned by company insiders.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $235.74 on Monday. The company has a current ratio of 2.78, a quick ratio of 2.71 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The firm’s fifty day simple moving average is $259.03 and its 200 day simple moving average is $260.14. The firm has a market capitalization of $30.67 billion, a price-to-earnings ratio of -108.64 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.03). As a group, equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.